Skip Ribbon Commands
Skip to main content
PHO Rounds: Microbiology- Next Generation Sequencing Panel Development in the Clinical Lab: A Bit of a Change
Friday, May 22, 2015 02:00 pm to 03:00 pm
Venue: by webinar only
Topic:
Infectious Diseases; Laboratory Testing and Sciences; Research and Collaboration
City: Toronto
Type:  
Format: Webinar

​Note: This is an open invitation, and may be forwarded to interested parties.

The introduction of Next Generation Sequencing (NGS) technology into clinical practice has enabled labs of all sizes to efficiently, accurately and simultaneously test multiple genes in a panel format for a single indication (diseases such as cancer, microbial assessments, etc). NGS implementation in a diagnostic setting is not without challenges, however, the largest consideration that burdens labs is the management of the large amount of data generated by this technology. Focusing on a few cancer syndromes and their complexities, Dr. Charames will describe the challenges of managing NGS data, asking the following: What do you keep? What can you discard?  How do you setup your lab for the future? We are rapidly approaching a time where ethics will overtake technological limitations as the bottleneck in molecular diagnostics; an exciting time as we move closer to individualized medicine.

Presenter: Dr. George Charames

Dr. George Charames is the Director of the Advanced Molecular Diagnostics Laboratory at Mount Sinai Hospital's Department of Pathology and Lab Medicine, and Assistant Professor in Lab Medicine and Pathobiology at the University of Toronto. Dr. Charames earned his MSc and PhD from the University of Toronto, and went on to complete a Clinical Molecular Genetics fellowship at the Johns Hopkins School of Medicine, before returning to Toronto. Dr. Charames has implemented Next Generation Sequencing technology in the molecular diagnostic lab for the detection of genes associated with Hereditary Breast and Ovarian Cancers; and he is currently adapting this technology for other cancers. His translational research interests are to use high throughput genomic sequencing, in addition to proteomics and biomarker discovery technologies, to improve individualized medicine.

PLEASE NOTE: We regret that CME credits cannot be provided for this session.

Questions

Stay up-to-date on upcoming events and calls for abstracts by visiting our calendar.
If you have submissions, or questions or comments about the items above, send them to learning@oahpp.ca.

Public Health Ontario is committed to complying with the Accessibility for Ontarians with Disabilities Act (AODA).
If you require accommodations to participate in this event, please contact 647-260-7100 or learning@oahpp.ca.

 

Uncontrolled print copy. Valid only on day of Print: [date]
Page updated on [date/time] 29/05/2015 8:38 AM
© , Ontario Agency for Health Protection and Promotion